Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-25T05:57:31.035Z Has data issue: false hasContentIssue false

Marked Response to VNS in a Post-Cingulotomy Patient: Implications for the Mechanism of Action of VNS in TRD

Published online by Cambridge University Press:  01 June 2011

Abstract

Treatment-resistant major depression (TRMD, major depressive disorder that fails to respond to numerous therapies) is a relatively common and clinically challenging disorder. In many cases, the most severely affected TRMD patients have received surgical intervention (subcaudate tractotomy, limbic leucotomy, anterior capsulotomy, and anterior cingulotomy). New treatments, including vagus nerve stimulation (VNS) and deep brain stimulation, have emerged to treat individuals with TRMD. We describe the case of a woman, 53 years of age, with a long and sustained history of TRMD (33 years), which was unresponsive to numerous treatments (multiple pharmacotherapies, psychotherapy, electroconvulsive therapy [ECT]). Additionally, her TRMD failed to respond to a bilateral anterior cingulotomy. She underwent placement of a cervical vagus nerve stimulator and a brief course of ECT (3 unilateral treatments). Her depression improved markedly, and it has remained in sustained remission for 3.5 years. This case suggests a potential synergistic effect of VNS and ECT, as well as provides possible clues to the neural circuitry of VNS in TRMD.

Type
Review Article
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Faculty Disclosures: Dr. Conway has received honoraria for being on the speaker's bureaus of Bristol-Myers Squibb, Merck, and Pfizer; and has received research support from Bristol-Myers Squibb. Mr. Gebretsakik and Mr. Bucholz report no affiliations with or financial interest in any organizations that may pose a conflict of interest.

References

Faculty Disclosures: Dr. Conway has received honoraria for being on the speaker's bureaus of Bristol-Myers Squibb, Merck, and Pfizer; and has received research support from Bristol-Myers Squibb. Mr. Gebretsakik and Mr. Bucholz report no affiliations with or financial interest in any organizations that may pose a conflict of interest.